Nimacimab monotherapy misses primary weight-loss endpoint, though combination with semaglutide shows promise, raising questions for the drug's future.
The China-based education firm's shares plummeted to an all-time low without any immediate news, deepening concerns over its financial stability and exchange listing.
The healthcare data firm will leverage Palantir's AI platform to enhance its real-world clinical data network, fueling investor optimism.
Needham and Cantor Fitzgerald initiate 'Buy' ratings while unconfirmed partnership rumors with Tesla fuel significant buying pressure.
Ascendiant Capital Markets raises its price target to $22, calling the e-commerce company 'very undervalued' after a stellar Q2 performance.
FDA grants Breakthrough Therapy status for a promising new drug targeting the rare and fatal Sanfilippo Syndrome Type B.
The biotech firm secured its sixth approval for the ZORYVE franchise, expanding its dermatology treatment to children as young as two.
Shares surged over 100% in after-hours trading following a $35.6 million investment to advance a strategic mining project in Alaska.